Steven M. Paul, MD

Karuna Therapeutics, Boston, Massachusetts

JCP
Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia
Narrative Review

August 19, 2024

While the pathophysiology of schizophrenia is complex, treatments with novel pharmacological actions that target these systems are of interest as adjunctive treatment for schizophrenia.
Bruce J. Kinon, Stefan Leucht, Carol Tamminga, et al
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
Peter J. Weiden, Alan Breier, Sarah Kavanagh, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe